BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 6895774)

  • 1. Tuftsin, a natural activator of phagocytic functions including tumoricidal activity.
    Najjar VA; Konopinska D; Chaudhuri MK; Schmidt DE; Linehan L
    Mol Cell Biochem; 1981 Dec; 41():3-12. PubMed ID: 6895774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antinociceptive action of the SP1-4 tetrapeptide and of some tuftsin analogs.
    Semion IZ; Nawrocka E; Słoń J; Tartar A; Obuchowicz E; Gołba K; Herman ZS
    Pol J Pharmacol Pharm; 1990; 42(4):393-401. PubMed ID: 1711198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The analgesic activity of some tuftsin- and tuftsin inhibitor-like fragments of the viral coat proteins.
    Obuchowicz E; Słoń JJ; Klin M; Madej A; Siemion IZ; Herman ZS
    Pol J Pharmacol; 1993; 45(3):269-79. PubMed ID: 8220660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antineoplastic effects of tuftsin and tuftsinyltuftsin on B16/5B melanoma and L1210 cells.
    Najjar VA; Linehan L; Konopińska D
    Ann N Y Acad Sci; 1983; 419():261-7. PubMed ID: 6324637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect of tuftsin.
    Nishioka K; Babcock GF; Phillips JH; Noyes RD
    Mol Cell Biochem; 1981 Dec; 41():13-8. PubMed ID: 6895773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo immunopharmacological properties of tuftsin (Thr-Lys-Pro-Arg) and some analogues.
    Florentin I; Chung V; Martinez J; Maral J; Le Garrec Y; Mathé G
    Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):73-80. PubMed ID: 2423822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The similarity between tuftsin (Thr-Lys-Pro-Arg) receptors and tuftsin antibody: a case of induced molecular mimicry.
    Chaudhuri MK; Konopińska D; Bump NJ; Najjar VA
    Ann N Y Acad Sci; 1983; 419():135-42. PubMed ID: 6324634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuftsin (an Ig-associated tetrapeptide) triggers the immunogenic function of macrophages: implications for activation of programmed cells.
    Tzehoval E; Segal S; Stabinsky Y; Fridkin M; Spirer Z; Feldman M
    Proc Natl Acad Sci U S A; 1978 Jul; 75(7):3400-4. PubMed ID: 277940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuftsin, a natural activator of phagocyte cells: an overview.
    Najjar VA
    Ann N Y Acad Sci; 1983; 419():1-11. PubMed ID: 6370072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunomodulatory activity of tetra- and tripeptides of tuftsin-kentsin group.
    Wieczorek Z; Zimecki M; Słoń JJ; Siemion IZ
    Peptides; 1994; 15(2):215-21. PubMed ID: 8008626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competition between tuftsin and HBV S-protein sequences.
    Siemion IZ; Słoń J; Nawrocka E; Wieczorek Z
    Int J Pept Protein Res; 1990 May; 35(5):428-33. PubMed ID: 2376468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative evaluation of the effect of tuftsin and its analogs on immunogenesis].
    Val'dman AV; Ratnikov VI; Makarova NV; Kozlovskaia MM
    Biull Eksp Biol Med; 1982 Dec; 94(12):56-7. PubMed ID: 6897519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical aspects of tuftsin deficiency syndrome.
    Najjar VA
    Med Biol; 1981 Jun; 59(3):134-8. PubMed ID: 6895538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of tuftsin and rigin derivatives containing monosaccharides or monosaccharide derivatives.
    Rocchi R; Biondi L; Cavaggion F; Filira F; Gobbo M; Dagan S; Fridkin M
    Int J Pept Protein Res; 1987 Feb; 29(2):262-75. PubMed ID: 3570666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuftsin, Thr-Lys-Pro-Arg. Anatomy of an immunologically active peptide.
    Fridkin M; Gottlieb P
    Mol Cell Biochem; 1981 Dec; 41():73-97. PubMed ID: 7035869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tuftsin--new analogues and properties].
    Wardowska A; Dzierzbicka K; Myśliwski A
    Postepy Biochem; 2007; 53(1):60-5. PubMed ID: 17718389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical and physiological aspects of tuftsin deficiency syndromes exhibiting defective phagocytosis.
    Najjar VA
    Klin Wochenschr; 1979 Aug; 57(15):751-6. PubMed ID: 385971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the peptide chain length of new elongated tuftsin analogs on phagocytosis process.
    Konopińska D; Kazanowska B; Bogusławska-Jaworska J
    Int J Pept Protein Res; 1984 Sep; 24(3):267-73. PubMed ID: 6594319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competition between tuftsin and HIV-1, HIV-2 envelope protein sequences.
    Siemion IZ; Słoń J; Wieczorek Z
    Arch Immunol Ther Exp (Warsz); 1991; 39(5-6):469-78. PubMed ID: 1841544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and functional studies of tuftsin analogs containing isopeptide bond.
    Mezö G; Szekerke M; Sármay G; Gergely J
    Peptides; 1990; 11(3):405-15. PubMed ID: 2381868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.